NF-κB/IκB

SU1261 is a potent inhibitor of IKK, displaying Ki values of 10 nM for IKKα and 680 nM for IKKβ. This compound effectively inhibits non-canonical NF-κB signaling pathways, making it a valuable tool for studying the role of IKK in various cellular processes. Its application in research, particularly in osteosarcoma cell models such as U2OS, can provide insights into inflammatory responses and oncogenic signaling mechanisms.

SR12343 is an IKK/NF-κB inhibitor that acts as a mimetic of the NF-κB essential modulator (NEMO)-binding domain. It effectively disrupts the interaction between IKKβ and NEMO, leading to inhibition of TNF-α- and LPS-induced NF-κB activation, with an IC50 of 37.02 μM for TNF-α-mediated pathways. SR12343 has been shown to reduce LPS-induced acute pulmonary inflammation in murine models, making it valuable for research into inflammatory and degenerative diseases.

TBK1/IKKε-IN-4 is a selective inhibitor of TBK1 and IKKε, characterized by its 6-aminopyrazolopyrimidine structure. With IC50 values of 13 nM and 59 nM for TBK1 and IKKε, respectively, this compound demonstrates significant potency. It exhibits minimal activity against other protein kinases, including PDK1, PI3K family members, and mTOR, making it an efficient tool for investigating TBK1/IKKε-related pathways in various biological contexts. This inhibitor is useful for studies in inflammation, immune response, and neurodegenerative diseases.

BOT-64 is a selective IκB kinase β (IKKβ) inhibitor with an IC50 value of 1 µM. This compound effectively inhibits lipopolysaccharide-induced activation of nuclear factor-κB (NF-κB) and the subsequent transcription of NF-κB-regulated inflammatory genes. BOT-64 is valuable for research into inflammatory pathways and NF-κB signaling, providing insights into potential therapeutic strategies for inflammatory diseases.

IKK2-IN-4 is a selective inhibitor of IKK-2, exhibiting a potent IC50 value of 25 nM. This compound effectively inhibits LPS-induced TNFα production in peripheral blood mononuclear cells (PBMCs), making it a valuable tool for studying inflammatory responses. Research applications include investigations into signaling pathways involved in inflammation and potential therapeutic strategies for immune-related disorders.

HPN-01 is a potent and selective inhibitor of IκB kinase (IKK), demonstrating pIC50 values of 6.4, 7.0, and <4.8 for IKK-α, IKK-β, and IKK-ε, respectively. This compound exhibits significant selectivity, showing more than 50-fold preference over a diverse panel of over 50 kinases, including ALK5, CDK-2, EGFR, ErbB2, GSK3β, PLK1, Src, and VEGFR-2. HPN-01 is a valuable tool for research applications focused on inflammatory pathways, cancer cell signaling, and the study of immune responses.

IKKβ-IN-4 is a selective inhibitor of IkappaB kinase-β (IKKβ), with an IC50 value of 1.9 μM. IKKβ plays a crucial role in the NF-κB signaling pathway, which is implicated in various diseases, including inflammation and cancer. This compound is utilized in research to study the modulation of NF-κB activity and its potential therapeutic applications in related disease models.

MLN120B dihydrochloride is a potent inhibitor of IKKβ, exhibiting competitive ATP binding with an IC50 of 60 nM. This compound effectively inhibits the growth of multiple myeloma cells both in vitro and in vivo, making it a valuable tool for cancer research. Additionally, MLN120B can be utilized in studies focused on rheumatoid arthritis, contributing to the understanding of inflammatory pathways and potential therapeutic interventions.

IKK2-IN-3 is a selective inhibitor of IKK2, demonstrating a potent inhibitory effect with an IC50 value of 0.075 μM. This compound effectively disrupts the NF-κB signaling pathway, impacting various cellular processes such as inflammation and immune response. IKK2-IN-3 is suitable for research applications involving the modulation of IKK2 activity in disease models and studying the role of NF-κB in cellular signaling.

LY2409881 is a selective inhibitor of IκB kinase β (IKK2), demonstrating potent inhibition with an IC50 of 30 nM. This compound is primarily used in research for its ability to modulate the NF-κB signaling pathway, making it relevant for studying inflammation, cancer, and autoimmune diseases. Researchers utilize LY2409881 to explore its therapeutic potential in various disease models and to investigate the role of IKK2 in cellular processes.

PS-1145 dihydrochloride is a selective inhibitor of IκB kinase-2, exhibiting an IC50 value of 88 nM. This compound effectively inhibits the phosphorylation of IκB kinase, thereby suppressing NF-κB activity. PS-1145 dihydrochloride is utilized in research applications targeting inflammatory responses and cancer biology.

IKK-IN-4 is a selective inhibitor of IkappaB kinase 2 (IKKβ), exhibiting an IC50 of 45 nM for IKKβ and 650 nM for IKKα. This compound is instrumental in research focusing on the NF-κB signaling pathway and its regulation, providing insights into inflammation, cancer, and other diseases linked to IKK activity. IKK-IN-4 serves as a valuable tool for studying IKKβ-mediated signaling mechanisms and potential therapeutic interventions.

SR8185 is a potent dual inhibitor of TBK1 and IKKi, exhibiting IC50 values of 3 nM and less than 10 nM, respectively. This compound demonstrates significant antiproliferative effects across a wide range of human cancer cell lines. SR8185 is ideal for exploring cancer-related pathways and therapeutic strategies in cancer research.

IKKβ-IN-1 is a selective inhibitor of IkappaB kinase beta (IKK-β), exhibiting an IC50 of 0.20 μM. This compound effectively reduces the production of pro-inflammatory cytokines such as PGE2 and TNF-α in mouse macrophage cells. Additionally, IKKβ-IN-1 has demonstrated protective effects against mortality in mice subjected to septic shock, highlighting its potential for research in inflammation and immune response.

TBK1/IKKε-IN-6 is a selective inhibitor of TBK1 and IKKε, exhibiting IC50 values below 100 nM for both targets. This compound plays a significant role in modulating inflammatory signaling pathways by inhibiting the activation of these kinases. It is particularly useful in research focused on autoimmune diseases, cancer, and viral infections, enabling the exploration of therapeutic strategies targeting the TBK1/IKKε pathway.

(E/Z)-HOIPIN-1 is a selective inhibitor of the linear ubiquitin chain assembly complex (LUBAC), targeting the IκB kinase (IKK) pathway. With an IC50 value greater than 2.8 μM, this compound effectively inhibits LUBAC-mediated NF-κB activation. Its potential applications include studies of inflammatory responses, cancer biology, and the modulation of immune signaling pathways.

SAR113945 is a highly potent inhibitor of IKK-β, exhibiting an IC50 value of 0.4 nM. This compound is primarily utilized in research focusing on inflammatory pathways and oncogenic processes. Its efficacy makes it a valuable tool for investigating the role of IKK-β in various disease states, particularly in understanding mechanisms underlying inflammation and cancer progression.

MLN-0415 is an inhibitor of IKKβ, a key regulator in the NF-κB signaling pathway. This compound exhibits significant anti-inflammatory activity and is instrumental in researching conditions such as arthritis and other inflammatory diseases. MLN-0415 facilitates the exploration of therapeutic strategies targeting the modulation of inflammatory responses.

(Rac)-PF-184 is a selective inhibitor of the inhibitor of κB kinase 2 (IKK-2) with an IC50 value of 37 nM. This compound exhibits significant anti-inflammatory properties, making it a valuable tool for research into inflammatory signaling pathways. It is suitable for studies investigating the role of IKK-2 in various biological processes and disease models.

1-Dehydro-[10]-gingerdione functions as a selective inhibitor of IKKβ by targeting its activation loop, leading to the disruption of IKKβ-mediated phosphorylation of IκBα in macrophages stimulated with various agonists. This compound effectively inhibits LPS-induced NF-κB transcriptional activity. 1-Dehydro-[10]-gingerdione holds promise for research into NF-κB-related inflammation and autoimmune disorders.

IKK-IN-3 is a potent and selective inhibitor of IkappaB kinase 2 (IKK2, also known as IKKβ), exhibiting IC50 values of 19 nM for IKK2 and 400 nM for IKK1 (IKKα). This compound is valuable in research focused on the regulation of the NF-kB signaling pathway, which plays a critical role in inflammation, immune responses, and cancer progression. IKK-IN-3 can be utilized to investigate the therapeutic potential of IKK2 inhibition in various disease models.

CGA-JK3 is an ATP-competitive inhibitor of IκB kinase (IKKβ), effectively hindering its kinase activity. This compound inhibits the phosphorylation of IκBα in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells, demonstrating its potential in studying inflammatory signaling pathways. CGA-JK3 is useful for researchers investigating the modulation of NF-κB signaling and related biological processes.

GTCpFE is a selective inhibitor of IKKα/β, functioning within the NF-κB signaling pathway. This compound exhibits significant anti-inflammatory properties by preventing the nuclear translocation of the p65 subunit of NF-κB. Additionally, GTCpFE demonstrates targeted anti-cancer stem-like cell activity by impairing mammosphere formation and reducing the CD44+ CD24- immunophenotype associated with aggressive breast cancer. Its dual mechanism positions GTCpFE as a promising agent for both inflammation and cancer research.

TBK1/IKKε-IN-1 is a potent dual inhibitor of TBK1 and IKKε, demonstrating IC50 values of less than 100 nM. This compound is valuable for research applications involving the modulation of inflammatory pathways and immune responses. Its inhibition of these kinases provides a tool for studying their roles in various biological processes and disease states, particularly those related to cancer and neuroinflammation.

PI3K/PIKK-IN-2 is a potent inhibitor of the phosphoinositide 3-kinase (PI3K) and phosphoinositide-dependent kinase (PIKK) pathways. This compound demonstrates significant biological activity by modulating signaling pathways involved in cell growth, metabolism, and survival. PI3K/PIKK-IN-2 is suitable for use in research applications focused on targeted therapies, including the development of antibody-drug conjugates (ADCs).

Gabexate mesylate is a competitive proteasome inhibitor, primarily targeting serine proteinases such as thrombin and Factor Xa. It exhibits diverse biological activity, including anticoagulant effects by modulating thrombin activity and anti-inflammatory properties through the inhibition of NF-κB and proinflammatory cytokines. Gabexate mesylate is commonly utilized in research focused on pancreatitis and disseminated intravascular coagulation, making it a valuable reagent for studies in hemostasis and inflammation.

Erdosteine functions as a bacterial inhibitor by inhibiting lipopolysaccharide (LPS)-induced activation of NF-κB. This compound exhibits muco-modulatory, anti-bacterial, anti-inflammatory, and antioxidant properties. Erdosteine is primarily utilized in research applications focused on respiratory disorders and inflammation, supporting the study of therapeutic interventions in these areas.

Isoquercitrin is a potent nitric oxide synthase inhibitor with significant antioxidant and anti-inflammatory properties. This naturally occurring polyphenol exerts protective effects against ethanol-induced hepatotoxicity and oxidative stress, primarily through the activation of the Nrf2/ARE signaling pathway. Additionally, Isoquercitrin modulates the expression of nitric oxide synthase 2 (NOS2) via the nuclear factor-κB (NF-κB) regulatory mechanism. Due to its high bioavailability and low toxicity, Isoquercitrin presents potential applications in research on metabolic disorders and the prevention of birth defects in diabetic pregnancies.

Benzoyloxypaeoniflorin is a potent tyrosinase inhibitor derived from the root of Paeonia suffruticosa, exhibiting an IC50 value of 0.453 mM against mushroom tyrosinase. Additionally, it functions as an NF-κB inhibitor, contributing to enhanced blood circulation by inhibiting platelet aggregation and blood coagulation. This compound is of significant interest in research applications focused on skin disorders and inflammation.

Flaconitine is a potent inhibitor of the NF-κB signaling pathway. This compound has been shown to effectively block the activation of NF-κB, thus modulating inflammatory responses. Flaconitine is widely used in research focused on immunology, cancer biology, and studies involving inflammatory diseases. Its ability to regulate gene expression through NF-κB inhibition makes it a valuable tool for investigating cellular signaling and therapeutic pathways.

Tolterodine is an mAChR inhibitor that competitively binds to acetylcholine, leading to a reduction in sympathetic excitation and inhibition of involuntary bladder muscle contractions. It is known to restore the Nrf2/NF-κB signaling pathway, providing protection against inflammatory responses and ferroptosis. Additionally, Tolterodine mitigates LPS-induced reactive oxygen species production and lipid oxidation, making it valuable for research in urinary tract infections and overactive bladder conditions.

RN-0001 is a potent inhibitor of cyclophilins, specifically demonstrating Ki values of 4.1 nM and 12.0 nM against Cyclophilin A (CypA) and Cyclophilin D (CypD), respectively. By directly binding to CypD, RN-0001 effectively inhibits its peptidyl-prolyl cis-trans isomerase activity, preventing mitochondrial permeability transition pore opening. This compound enhances mitochondrial function, diminishes reactive oxygen species (ROS) production, and downregulates lipogenic marker expression. Additionally, RN-0001 inhibits NF-κB p65 nuclear translocation and reduces the release of activated caspase-3 and cytochrome c, making it a valuable tool for investigating alcohol-associated liver disease.

HDAC2-IN-3 is a selective HDAC2 inhibitor with an IC50 of 14 nM, capable of crossing the blood-brain barrier. This compound effectively upregulates histone acetylation levels both in cultured cells and in vivo, and has been shown to enhance long-term potentiation (LTP) in the hippocampus. HDAC2-IN-3 is valuable for research applications focused on neurodegenerative disorders, particularly Alzheimer's disease.

HDAC8-IN-16 is a selective inhibitor of histone deacetylase 8 (HDAC8), exhibiting an IC50 of 0.16 μM. It has been shown to induce apoptosis in various cell lines, trigger G2/M phase cell cycle arrest, and moderately inhibit cancer cell proliferation. This compound is particularly relevant for research applications related to colorectal cancer, providing valuable insights into the therapeutic potential of HDAC8 modulation.

HDAC6-IN-78 is a highly selective inhibitor of histone deacetylase 6 (HDAC6), exhibiting an IC50 of 24 nM. This compound demonstrates specificity by showing no significant activity against other HDAC isoforms. HDAC6-IN-78 is valuable for research applications focused on studying the role of HDAC6 in cellular processes, including neurodegenerative diseases and cancer.

NCT-10b is a selective inhibitor of HDAC6, primarily targeting this enzyme to influence cellular processes. It facilitates α-tubulin acetylation while having minimal effect on histone H4 acetylation. NCT-10b is applicable in research focused on multiple myeloma, providing insights into the mechanisms of this hematological malignancy and potential therapeutic strategies.

Rhynchophylline is an alkaloid compound characterized as an NF-κB inhibitor. It exhibits significant biological activity with potential applications in anti-inflammatory and neuroprotective research. This compound is derived from Uncaria rhynchophyllum and is of interest for studies investigating the modulation of inflammatory pathways and neuronal protection mechanisms.